A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology
- PMID: 20116457
- PMCID: PMC2831115
- DOI: 10.1016/j.cct.2010.01.003
A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology
Abstract
The National Institute on Drug Abuse Clinical Trials Network launched the Prescription Opioid Addiction Treatment Study (POATS) in response to rising rates of prescription opioid dependence and gaps in understanding the optimal course of treatment for this population. POATS employed a multi-site, two-phase adaptive, sequential treatment design to approximate clinical practice. The study took place at 10 community treatment programs around the United States. Participants included men and women age > or =18 who met Diagnostic and Statistical Manual, 4th Edition criteria for dependence upon prescription opioids, with physiologic features; those with a prominent history of heroin use (according to pre-specified criteria) were excluded. All participants received buprenorphine/naloxone (bup/nx). Phase 1 consisted of 4 weeks of bup/nx treatment, including a 14-day dose taper, with 8 weeks of follow-up. Phase 1 participants were monitored for treatment response during these 12 weeks. Those who relapsed to opioid use, as defined by pre-specified criteria, were invited to enter Phase 2; Phase 2 consisted of 12 weeks of bup/nx stabilization treatment, followed by a 4-week taper and 8 weeks of post-treatment follow-up. Participants were randomized at the beginning of Phase 1 to receive bup/nx, paired with either Standard Medical Management (SMM) or Enhanced Medical Management (EMM; defined as SMM plus individual drug counseling). Eligible participants entering Phase 2 were re-randomized to either EMM or SMM. POATS was developed to determine what benefit, if any, EMM offers over SMM in short-term and longer-term treatment paradigm. This paper describes the rationale and design of the study.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.Am J Addict. 2014 Jul-Aug;23(4):343-8. doi: 10.1111/j.1521-0391.2013.12105.x. Epub 2013 Sep 24. Am J Addict. 2014. PMID: 24112096 Free PMC article. Clinical Trial.
-
Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. doi: 10.1001/archgenpsychiatry.2011.121. Epub 2011 Nov 7. Arch Gen Psychiatry. 2011. PMID: 22065255 Free PMC article. Clinical Trial.
-
Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?Drug Alcohol Depend. 2014 Jul 1;140:118-22. doi: 10.1016/j.drugalcdep.2014.04.005. Epub 2014 Apr 24. Drug Alcohol Depend. 2014. PMID: 24831754 Free PMC article. Clinical Trial.
-
Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.J Addict Nurs. 2019 Oct/Dec;30(4):254-260. doi: 10.1097/JAN.0000000000000308. J Addict Nurs. 2019. PMID: 31800516
-
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".Addict Sci Clin Pract. 2021 Mar 6;16(1):15. doi: 10.1186/s13722-021-00223-z. Addict Sci Clin Pract. 2021. PMID: 33676577 Free PMC article. Review.
Cited by
-
Prescription opioid abuse: challenges and opportunities for payers.Am J Manag Care. 2013 Apr;19(4):295-302. Am J Manag Care. 2013. PMID: 23725361 Free PMC article.
-
Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010.Open Med. 2012 Apr 10;6(2):e41-7. Print 2012. Open Med. 2012. PMID: 23696768 Free PMC article.
-
Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.J Subst Abuse Treat. 2015 May;52:48-57. doi: 10.1016/j.jsat.2014.12.011. Epub 2014 Dec 30. J Subst Abuse Treat. 2015. PMID: 25601365 Free PMC article.
-
Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.Am J Drug Alcohol Abuse. 2014 Mar;40(2):157-62. doi: 10.3109/00952990.2013.842241. Epub 2013 Nov 12. Am J Drug Alcohol Abuse. 2014. PMID: 24219166 Free PMC article. Clinical Trial.
-
Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.Exp Clin Psychopharmacol. 2015 Dec;23(6):428-35. doi: 10.1037/pha0000039. Epub 2015 Aug 24. Exp Clin Psychopharmacol. 2015. PMID: 26302337 Free PMC article. Clinical Trial.
References
-
- Volkow ND. Confronting the rise in abuse of prescription drugs. NIDA Notes. 2005;19(5):3.
-
- Janofsky M. Drug-Fighters Turn to Rising Tide of Prescription Abuse. The New York Times; Mar 18, 2004.
-
- Substance Abuse and Mental Health Services Administration. DAWN Series D-30. Rockville, MD: 2008. Drug Abuse Warning Network 2006: National Estimates of Drug-Related Emergency Department Visits.
-
- Substance Abuse and Mental Health Services Administration. NSDUH Series H-34. Rockville, MD: Office of Applied Studies; 2008. Results from the 2007 National Survey on Drug Use and Health: National Findings.
-
- Substance Abuse and Mental Health Services Administration Office of Applied Studies. DASIS Series: S-45. National Admissions to Substance Abuse Treatment Services; Rockville, MD: 2009. Treatment Episode Data Set (TEDS). Highlights - 2007.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous